Takeda and HUTCHMED Reports P-III Study (FRESCO2) Results of Fruquintinib in the P-III Study (FRESCO-2) for Metastatic Colorectal Cancer
Shots:
- The P-III study results published in The Lancet evaluating fruquintinib + BSC vs PBO + BSC in 691 patients with previously treated metastatic CRC. The study was conducted in the US, EU, Japan & Australia
- The study met its 1EPs & 2EPs i.e., improvement in OS & PFS, m-OS (7.4 vs 4.8mos.), m-PFS (3.7 vs 1.8mos.), DCR (56% vs 16%) while the median duration of follow-up was ~11mos. for patients in both groups. The safety profile was consistent with prior reported studies
- Grade ≥3 or higher AEs were reported in 63% vs 50%, and treatment discontinuation due to AEs (20% vs 21%). The therapy was approved for marketing in China in Sept 2018 & was commercially launched in China in Nov 2018 under the brand name Elunate
Ref: Businesswire | Image: Takeda
Related News:- Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
